Bristol Myers Squibb: Phase 3 Data on Cancer Drug Validate the Expansion of Precision Oncology
Reading Time: 3 minutes
The company focuses on acquisitions to offset revenue declines due to expiring patents. The active ingredient RYZ101 achieved the primary endpoint in a Phase 3 clinical study for tumors. The improvement in progression-free survival supports the company's current strategy. Focus on the Growth Portfolio Bristol Myers Squibb (BMY) (i.) is in a consolidation phase. The pharmaceutical company, which anticipates revenues between $49 billion and $50 billion for the year 2026, needs to compensate for foreseeable revenue declines from older drugs....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
